A native antigen “reverse capture” microarray platform for autoantibody profiling of prostate cancer sera
暂无分享,去创建一个
Joshua R. Ehrlich | J. Richie | J. Ehrlich | W. Qiu | M. O'Leary | Robert J. Caiazzo | B. Liu | Oliver W. Tassinari
[1] A. Stromberg,et al. Profiling Tumor-Associated Antibodies for Early Detection of Non-small Cell Lung Cancer , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[2] J. Patard,et al. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players. , 2006, The Prostate.
[3] S. Avrameas,et al. Preferential recognition of the phosphorylated major linear B‐cell epitope of La/SSB 349–368aa by anti‐La/SSB autoantibodies from patients with systemic autoimmune diseases , 2006, Clinical and experimental immunology.
[4] Weiliang Qiu,et al. Development of a “reverse capture” autoantibody microarray for studies of antigen‐autoantibody profiling , 2006, Proteomics.
[5] Po-ki Ho,et al. Mammalian initiator apoptotic caspases , 2005, The FEBS journal.
[6] Debashis Ghosh,et al. Autoantibody signatures in prostate cancer. , 2005, The New England journal of medicine.
[7] T. Visakorpi,et al. Alterations of androgen receptor in prostate cancer , 2004, The Journal of Steroid Biochemistry and Molecular Biology.
[8] David E. Misek,et al. Development of natural protein microarrays for diagnosing cancer based on an antibody response to tumor antigens. , 2004, Journal of proteome research.
[9] A. Tramontano,et al. Conformation and Glycosylation of a Megalin Fragment Correlate with Nephritogenicity in Heymann Nephritis 1 , 2004, The Journal of Immunology.
[10] E. Lapointe,et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin , 2004, Arthritis research & therapy.
[11] E. Smeland,et al. Serological cloning of cancer/testis antigens expressed in prostate cancer using cDNA phage surface display , 2004, Cancer Immunology, Immunotherapy.
[12] Erik J. Erlandson,et al. Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity , 2003, Proteomics.
[13] J. Koziol,et al. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[14] G A Whitmore,et al. Power and sample size for DNA microarray studies , 2002, Statistics in medicine.
[15] Francis D. Gibbons,et al. Judging the quality of gene expression-based clustering methods using gene annotation. , 2002, Genome research.
[16] S. J. Monahan,et al. Serological cloning of PARIS-1: a new TBC domain-containing, immunogenic tumor antigen from a prostate cancer cell line. , 2002, Biochemical and biophysical research communications.
[17] Edward S. Kim,et al. Epidermal growth factor receptor biology (IMC-C225) , 2001, Current opinion in oncology.
[18] D. Johnston,et al. The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: relation to biopsy strategy. , 2001, The Journal of urology.
[19] T. Soussi,et al. Detection of p73 antibodies in patients with various types of cancer: immunological characterization , 2001, British Journal of Cancer.
[20] G. Ronquist,et al. Autoantibodies to Prostasomes as New Markers for Prostate Cancer , 2001, Upsala journal of medical sciences.
[21] T. Soussi,et al. p53 Antibodies in the sera of patients with various types of cancer: a review. , 2000, Cancer research.
[22] M. Brawer,et al. Prostate‐specific antigen: Current status , 1999, CA: a cancer journal for clinicians.
[23] G. Núñez,et al. Caspases: the proteases of the apoptotic pathway , 1998, Oncogene.
[24] M. Montenarh,et al. p53 autoantibodies in patients with urological tumours. , 1998, British journal of urology.
[25] E. Silbergeld,et al. P53 mutations associated with breast, colorectal, liver, lung, and ovarian cancers. , 1996, Environmental health perspectives.
[26] A. Arnold,et al. PRAD1/lCyclin D1 proto‐oncogene: Genomic organization, 5′ dna sequence, and sequence of a tumor‐specific rearrangement breakpoint , 1993 .
[27] R. Hiipakka,et al. Anti-5α-Reductase Autoantibodies in the Serum of Patients with Prostatic Cancer , 1990 .
[28] A. Jemal,et al. Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.
[29] Joshua R. Ehrlich,et al. The 'reverse capture' autoantibody microarray:a native antigen-based platform for autoantibody profiling , 2006, Nature Protocols.
[30] Jian-ying Zhang. Tumor-associated antigen arrays to enhance antibody detection for cancer diagnosis. , 2004, Cancer detection and prevention.
[31] F. Hodi,et al. MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients. , 2003, Cancer immunity.
[32] Kim-Anh Do,et al. Fingerprinting the circulating repertoire of antibodies from cancer patients , 2003, Nature Biotechnology.
[33] P. Lipponen,et al. Expression of cyclin A and D proteins in prostate cancer and their relation to clinopathological variables and patient survival. , 1999, The Prostate.
[34] L. Bonetta,et al. CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1. , 1994, Oncogene.
[35] R. Hiipakka,et al. Anti-5 alpha-reductase autoantibodies in the serum of patients with prostatic cancer. , 1990, The Journal of clinical endocrinology and metabolism.